Indication
Transthyretin-Related
4 clinical trials
4 products
Clinical trial
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)Status: Completed, Estimated PCD: 2017-08-01
Product
PatisiranProduct
Sterile Normal SalineClinical trial
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)Status: Active (not recruiting), Estimated PCD: 2028-04-15
Product
AcoramidisClinical trial
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With PolyneuropathyStatus:
Clinical trial
Screening for Cardiac Amyloidosis With Nuclear Cardiology for Minority PopulationsStatus: Recruiting, Estimated PCD: 2024-06-01
Product
99mTc-PYP